Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration

By: via Benzinga
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced it filed an amendment to its ongoing Phase 2 clinical study of MM-121 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.